Turn Therapeutics' topical GX-03 hit EASI-50 in 93% of eczema patients at four weeks.
Bradley Burnam, Turn Therapeutics CEO
June 1, 2026 08:51 AM EDT
Turn Therapeutics' eczema drug shows rapid response in mid-stage data
Ayisha Sharma
News Reporter
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis…
More adults with moderate to severe atopic dermatitis receiving an investigational extended-release topical formulation vs. a…
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36…
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which…
Triveni Bio closes a $65M Series C to fund two eczema drug candidates targeting kallikreins and IL-13, with Phase 2a data on lead…
